Bacterial Meningitis

Bacterial meningitis is a life-threatening inflammatory syndrome of the leptomeninges and the underlying subarachnoid cerebrospinal fluid (CSF) caused by bacterial invasion. This condition represents a medical and neurosurgical emergency characterized by rapid clinical deterioration and a high risk of permanent neurological sequelae ^[1]A1b[9]A1a.

Also Called / Synonyms

• Acute bacterial meningitis (ABM)
• Pyogenic meningitis
• Purulent meningitis
• Community-acquired bacterial meningitis (CABM)
• Healthcare-associated meningitis (HCAM)

Classification and Taxonomy

Bacterial meningitis is classified by its clinical onset, the environment of acquisition, and the specific causative pathogen. While viral meningitis often follows a benign course, bacterial meningitis in children carries a 2.0% mortality rate, compared to 0.002% for viral etiologies ^[7]B2c.

Clinical Significance and Terminology

Establishing a precise vocabulary is essential for risk stratification and management . In pediatric populations, the hospitalization rate for bacterial meningitis has declined by 50.0% (from 3.4 to 1.7 per 100,000) between 2010 and 2018, yet the mortality for those under age 1 remains high at 4.2% ^[7]B2c.

• Aseptic Meningitis: A clinical syndrome of meningeal inflammation where routine bacterial cultures are negative; while often viral, it can include partially treated bacterial cases.
• Tuberculous Meningitis (TBM): A specific form of bacterial meningitis caused by Mycobacterium tuberculosis. In adults with TBM, the frequency of HIV co-infection is approximately 38.0% ^[6]A1a.
• Post-Meningitic Epilepsy: A long-term complication where the 10-year risk of epilepsy is 4.1% following bacterial meningitis, compared to 1.2% in unexposed controls ^[3]B3b.

Bacterial meningitis remains a significant driver of long-term morbidity, with an overall complication rate of 37.3% in survivors of childhood infection ^[9]A1a. These sequelae include cognitive impairment (21.6%), emotional or behavioral problems (15.3%), and hearing loss (14.3%) ^[9]A1a. Understanding these classifications facilitates the transition into the underlying mechanisms of neural injury.

Pearl: Always distinguish between pyogenic and tuberculous meningitis early, as the latter requires specific scoring systems for diagnosis and carries a high (38%) association with HIV in adults ^[6]A1a[8]B2b.

The transition from systemic colonization to central nervous system (CNS) infection requires a coordinated sequence of bacterial translocation across the blood-brain-barrier (BBB) and the subsequent induction of a dysregulated neuroinflammatory cascade ^[12]D5[20]D5. While the virtual eradication of Haemophilus influenzae type B via vaccination has shifted the adult burden toward Streptococcus pneumoniae, the fundamental mechanisms of meningeal invasion remain centered on the subarachnoid space and the cerebral microvasculature ^[10]D5[12]D5.

Mechanisms of CNS Invasion

Bacterial entry into the CNS occurs through several distinct molecular pathways that compromise the structural integrity of the BBB:

1. Adhesion and Invasion: Pathogens utilize specific virulence factors, such as the GimA island-encoded IbeA in Escherichia coli K1, to mediate adhesion to human brain microvascular endothelial cells (HBMECs) ^[17]D5.
2. Cytoskeletal Reorganization: IbeA activates the Vimentin-NF-κB signaling pathway, triggering cytoplasmic mobilization and nuclear translocation of Vimentin, which facilitates bacterial traversal ^[17]D5.
3. Tight Junction Disruption: Infection leads to the concordant downregulation of the tight junction protein ZO-1 at both transcriptomic and proteomic levels, directly increasing paracellular permeability ^[16]D5.
4. Metabolic and Signaling Dysregulation: Pathogens suppress TGF-β/SMAD signaling and induce glycosaminoglycan degradation, further weakening the endothelial barrier ^[16]D5.

Neuroinflammatory Cascade and Host Response

Once bacteria reach the subarachnoid space, they are recognized by the innate immune system, primarily through microglial receptors ^[20]D5. This recognition triggers a "cytokine storm" involving IL-1β and TNF-α, which drives neutrophil infiltration and secondary tissue damage ^[20]D5.

Host susceptibility is significantly influenced by genetic polymorphisms. The TLR4 rs4986790 polymorphism is strongly associated with susceptibility to both meningococcal and pneumococcal meningitis ^[15]A1a. Meta-analysis data indicates a correlation between the GG + GA vs. AA genotypes and reduced risk (OR 0.34, 95%, p = 0.01), suggesting that Toll-like receptor efficiency dictates the early host response ^[15]A1a.

Neuroanatomic Consequences and Intracranial Pressure

The inflammatory response results in three primary forms of cerebral edema: vasogenic (due to BBB breakdown), cytotoxic (from bacterial toxins and neutrophil degranulation), and interstitial (secondary to impaired CSF outflow) ^[20]D5. These processes culminate in elevated intracranial pressure (ICP), which poses a critical risk for brain herniation ^[14]A1a.

Endogenous Repair and Neurogenesis

In response to the noxious stimuli of bacterial infection, the brain attempts an endogenous repair mechanism. Proliferation of neural progenitors is significantly increased in the dentate gyrus following bacterial meningitis compared to controls (p = 0.0075) ^[11]C4. This is evidenced by higher densities of cells expressing proliferating cellular nuclear antigen (PCNA) and immature neuronal markers such as TUC-4 (p = 0.0067) and doublecortin (p = 0.045) ^[11]C4.

Controversies and Guideline Disagreement

Pearl: The severity of bacterial meningitis is driven less by the bacterial load itself and more by the host's dysregulated inflammatory response to bacterial cell wall components, which justifies the use of adjunctive dexamethasone to modulate this cascade ^[10]D5[12]D5.

The global burden of meningitis remains substantial despite significant declines in incidence following the introduction of conjugate vaccines ^{[27]B2c[33]D5}. In 2023, there were approximately 2.54 million incident cases and 259,000 deaths worldwide ^[27]B2c. While mortality and incidence have decreased since 1990, children younger than 5 years still account for more than a third of all deaths (86,600) ^[27]B2c. In the United States, the incidence of bacterial meningitis fell by 31% between 1998 and 2007, reaching 1.38 cases per 100,000 population ^[26]B2c. This shift has transitioned the primary burden of disease from young children to older adults, with the median age of patients increasing from 30.3 to 41.9 years over the same period ^[26]B2c.

Etiologic Distribution

The microbial landscape is dominated by three primary pathogens, Streptococcus pneumoniae , Neisseria meningitidis , and Haemophilus influenzae , which account for the majority of acute cases globally ^[34]D5. Since the virtual eradication of H. influenzae type b (Hib) in high-income countries via vaccination, S. pneumoniae has emerged as the leading cause of bacterial meningitis beyond the neonatal period ^{[10]D5[26]B2c}.

• Streptococcus pneumoniae: The predominant species in the U.S. (58.0%) and Denmark (37%), associated with high mortality (up to 30%) and systemic complications in the elderly ^{[24]C4[26]B2c[45]B2b}.
• Group B Streptococcus (GBS): The second most common cause in U.S. surveillance (18.1%), frequently affecting neonates and increasingly identified in older adults ^[26]B2c.
• Neisseria meningitidis: Responsible for approximately 13.9% of U.S. cases and 5% of Danish cases ^{[26]B2c[45]B2b}. It remains a major cause of epidemics, particularly in the African meningitis belt ^[34]D5.
• Listeria monocytogenes: A food-borne pathogen (3.4% of U.S. cases) that disproportionately affects the immunocompromised, elderly, and pregnant women, though it can cause rapidly progressive ventriculitis in healthy young adults ^{[25]C4[26]B2c}.
• Zoonotic Pathogens: Rare causes (e.g., Streptococcus suis) associated with specific animal contact or consumption of animal products ^[28]D5.

Risk Factors and Predisposing Conditions

Risk is stratified by age, immune status, and environmental exposures. In infants aged 60-90 days, the prevalence of bacterial meningitis among well-appearing febrile patients is low at 0.11% ^[38]A1a. Conversely, adults with active cancer have a 2.71 to 3.52-fold increased annual incidence of community-acquired bacterial meningitis compared to those without cancer ^[31]B2b.

Temporal and Seasonal Trends

Incidence often exhibits seasonal variation, particularly in the African meningitis belt where epidemics are linked to dry seasons ^[34]D5. While overall rates have declined, the emergence of non-vaccine pneumococcal serotypes and antimicrobial resistance (global benzylpenicillin resistance in S. pneumoniae is 27.4%) continues to challenge prevention efforts ^{[33]D5[41]A1a}.

Pearl: The median age of bacterial meningitis has shifted to the fifth decade of life in vaccinated populations, where Streptococcus pneumoniae now accounts for nearly 60% of cases and carries a 30% mortality rate ^{[24]C4[26]B2c}.

Building upon the epidemiological risk factors previously discussed, the clinical presentation of bacterial meningitis is defined by the rapid onset of meningeal irritation and systemic inflammation. While the classic triad of neck stiffness, fever, and altered mental status is widely taught, these features are frequently absent in combination, necessitating a high index of clinical suspicion ^[33]D5, ^[50]D5.

Presenting Symptoms

Symptoms typically progress rapidly, often reaching a clinical nadir within 24 to 48 hours. In adults, the presentation is dominated by signs of increased intracranial pressure and meningeal inflammation ^[12]D5, ^[33]D5.

• Fever: Present in approximately 98% of pediatric cases ^[53]B3b and most adults, though it may be blunted in the elderly or immunocompromised ^[31]B2b.
• Headache: Often described as severe and generalized; it is a hallmark of cases with preserved consciousness ^[45]B2b.
• Altered Mental Status: Ranges from mild lethargy to deep coma. A low Glasgow Coma Scale ( GCS ) score at presentation is a robust independent predictor of unfavorable outcome ^[24]C4, ^[37]B2b.
• Vomiting: Reported in 67.7% of pediatric pneumococcal cases ^[53]B3b and frequently seen in postoperative meningitis ^[55]B3b.

Neurological Examination Findings

The physical examination must focus on identifying signs of meningeal irritation and focal neurological deficits that suggest intracranial complications ^[24]C4.

• Meningismus: Neck stiffness (nuchal rigidity) is the most common sign, though its absence does not exclude the diagnosis, particularly in infants or the critically ill ^[33]D5, ^[55]B3b.
• Cranial Nerve Palsies: Identified as a key prognostic variable in the Dutch Meningitis Cohort; their presence significantly increases the risk of an unfavorable outcome (GOS 1-4) ^[24]C4, ^[37]B2b.
• Focal Deficits: Hemiparesis or brainstem signs may indicate secondary vascular complications, such as delayed cerebral thrombosis or stroke ^[47]C4, ^[54]B3b.
• Pupillary Abnormalities: In mechanically ventilated patients, abnormal pupillary responses are independent predictors of 90-day mortality (31.3% overall mortality in severe cases) ^[52]B3b.

Phenotypic Variants

Clinical phenotypes vary significantly based on the causative pathogen and the patient's baseline health status ^[45]B2b.

Red Flags and Atypical Presentations

Clinicians must remain vigilant for signs of rapid deterioration or non-classic presentations that delay life-saving intervention.

• Systemic Severity: Septic shock, acute kidney injury, and coagulation disorders are independent predictors of poor functional outcome ^[52]B3b.
• Pediatric Specifics: Infants under 12 months often lack classic signs, presenting instead with bulging fontanels (34.1%) and convulsions (48.4%) ^[53]B3b.
• Delayed Deterioration: Patients may show initial improvement on dexamethasone before sudden neurological decline 7-19 days later due to delayed cerebral thrombosis ^[47]C4.
• Chronic/Subacute Presentation: Atypical MRI features or failure to improve on empiric therapy should prompt consideration of "chronic meningitis" mimics, sometimes requiring meningocortical biopsy ^[49]C4.
• Post-infectious Adhesive Arachnoiditis : Can present years later with symptoms like man-in-the-barrel syndrome (proximal arm weakness) due to cord tethering ^[48]C4.

Pearl: The absence of the classic triad (fever, neck stiffness, altered mental status) does not rule out bacterial meningitis; however, the presence of at least two of these features, or a low GCS score, should trigger immediate CSF analysis and empiric therapy ^[33]D5, ^[37]B2b.

Building on the clinical suspicion of acute meningitis, the diagnostic workup must proceed with extreme urgency to confirm the presence of bacterial pathogens and identify intracranial complications. While the classic triad of fever, neck stiffness, and altered mental status is often absent, their presence or absence cannot definitively rule out the disease, making objective testing mandatory ^[33]D5, ^[12]D5. The diagnostic process centers on rapid cerebrospinal fluid (CSF) acquisition, though this may be preceded by neuroimaging in patients with specific risk factors for herniation ^[50]D5.

History and Physical

Clinicians must prioritize identifying signs of increased intracranial pressure or focal deficits that may complicate immediate lumbar puncture.

• Neurologic Assessment: Evaluate the Glasgow Coma Scale ( GCS ) or the Full Outline of Unresponsiveness (FOUR) score. The FOUR score provides superior predictive value in severe cases by assessing brainstem reflexes and respiration ^[62]B2b.
• Physical Signs: Elicit meningeal signs (Brudzinski, Kernig) and perform a detailed cranial nerve exam. Cranial nerve palsies are independent predictors of unfavorable outcomes ^[24]C4, ^[37]B2b.
• Systemic Signs: Monitor for septic shock, purpura fulminans (suggestive of Neisseria meningitidis ), and signs of parameningeal infection such as otitis, sinusitis, or mastoiditis ^[60]C4.

Gold-Standard Test

The gold standard for diagnosis is CSF analysis via lumbar puncture (LP), ideally performed within 1 hour of presentation ^[33]D5. A definitive diagnosis requires the presence of a bacterial pathogen in the CSF via Gram stain, culture, or molecular methods (PCR) in the setting of clinical meningitis ^[26]B2c.

Laboratory Studies

CSF analysis must include opening pressure, cell count with differential, glucose, and protein.

Novel biomarkers such as Heparin -Binding Protein (HBP) and Lipocalin-2 (LCN-2) show high accuracy in differentiating bacterial from viral etiologies, particularly when leukocyte counts are low (5-1,000 cells/mm³) ^[67]B2b, ^[68]B2b. The blood urea nitrogen to albumin (BUN/ALB) ratio on admission is a practical systemic biomarker; a ratio >5.13 is associated with a significantly increased risk of unfavorable 3-month outcomes ^[69]B3b.

Neuroimaging

Cranial CT or MRI is indicated prior to LP if the patient has a GCS <10, new-onset seizures, focal neurologic deficits, or is severely immunocompromised ^[50]D5.

• CT: Useful for identifying hydrocephalus (present in 5% of adults) or underlying disorders like mastoiditis ^[29]C4, ^[24]C4. However, CT may fail to visualize infratentorial subdural empyema ^[60]C4.
• MRI: The preferred modality for suspected complications. Diffusion-weighted imaging (DWI) is essential for detecting ischemic stroke (occurring in 16% of cases) and infratentorial empyema ^[59]A1a, ^[60]C4.

Diagnostic Algorithm

1. Assess for LP Contraindications: Check for focal deficits, GCS <10, or papilledema.
2. Immediate Action: If contraindications exist, draw blood cultures and start empiric antibiotics + dexamethasone immediately; then proceed to CT ^[50]D5.
3. Lumbar Puncture: If no contraindications, perform LP immediately. Send CSF for Gram stain, culture, biochemistry, and multiplex PCR ^[33]D5.
4. Molecular Testing: Use multiplex PCR panels (e.g., BioFire) for rapid identification. If standard panels are negative but suspicion remains high, consider off-label broader panels or next-generation sequencing (tNGS) for rare pathogens like Candida albicans or Proteus mirabilis ^[73]C4, ^[72]C4.

EEG and NCS/EMG

• EEG: Indicated if seizures are suspected or if the patient remains encephalopathic despite treatment. Seizures are an independent risk factor for acute neurologic complications in neonates ^[70]B3b.
• NCS/EMG: Indicated if progressive flaccid paralysis develops during or after treatment to evaluate for post-infectious Guillain-Barre syndrome ^[71]C4.

Pearl: Do not delay antibiotics for neuroimaging or LP in a deteriorating patient; a CSF leukocyte count <1,000 cells/mm³ or the presence of gram-positive cocci on Gram stain are early indicators of a high-risk clinical course ^[37]B2b, ^[24]C4.

Following the confirmation of diagnosis via cerebrospinal fluid (CSF) analysis, immediate risk stratification is required to identify patients at high risk for mortality and long-term neurological disability. Severity in bacterial meningitis is determined by the interplay of host factors, systemic inflammatory response, and the development of intracranial complications such as ischemic stroke or seizures .

Validated Clinical Risk Scores

Several scoring systems have been validated to predict unfavorable outcomes, defined as a Glasgow Outcome Scale (GOS) score of 1 to 4 or a modified Rankin Scale ( mRS ) score of 3 to 6 ^{[24]C4[37]B2b[52]B3b}.

• Dutch Meningitis Risk Score: This bedside tool utilizes six variables available within one hour of admission to predict unfavorable outcomes (C-index 0.84) ^[37]B2b.
• Age (increasing risk per year).
• Heart rate (tachycardia).
• Glasgow Coma Scale ( GCS ) score on admission.
• Presence of cranial nerve palsies.
• CSF leukocyte count < 1,000 cells/mm³.
• Gram-positive cocci on Gram stain ^[37]B2b.
• FOUR Score: The Full Outline of Unresponsiveness (FOUR) score provides superior predictive value in severely obtunded patients (GCS 3) by incorporating brainstem reflexes and respiration patterns ^[62]B2b. Motor, brainstem, and respiration items are independent predictors of mortality (AUC 0.68) ^[62]B2b.

Predictors of Unfavorable Outcome

Mortality and morbidity are largely driven by the initial neurological and systemic severity ^[52]B3b. In mechanically ventilated adults, independent predictors of 90-day unfavorable functional outcome include older age, septic shock , acute kidney injury, coagulation disorders, and abnormal brain imaging at presentation ^[52]B3b.

Age-Specific Stratification

Risk profiles shift significantly across the lifespan. In children, acute bacterial meningitis presenting as non-traumatic coma carries a case-fatality rate of 45% ^[51]A1a. While pediatric mortality is often lower than in adults (3% vs 30% in some cohorts), survivors face high rates of complications such as empyema and vasculitis-induced infarctions ^{[35]B2b[77]B3b}. In adults ≥ 60 years, systemic complications cause 59% of deaths, whereas neurological complications (e.g., brain herniation ) cause 65% of deaths in younger patients ^[24]C4.

Long-term Sequelae and Epilepsy Risk

Severity during the acute phase directly influences the risk of late-onset complications. The 10-year risk of epilepsy after bacterial meningitis is 4.1% ^[3]B3b. Risk factors for post-meningitis epilepsy include seizures during the index admission, mechanical ventilation, and persistent neurological deficits ^[3]B3b[36]D5. Neuropsychological sequelae, including impaired executive function and short-term memory, are more prevalent in patients with a GOS < 5 and correlate with lower brain volume and white matter lesions on MRI ^[75]B3b.

Pearl: A CSF leukocyte count < 1,000 cells/mm³ is a paradoxical marker of high severity, reflecting an overwhelmed immune response and predicting a significantly higher risk of death ^{[24]C4[37]B2b}.

Following the stratification of risk and severity, management must pivot immediately to the stabilization of life-threatening neurologic crises. The primary objective is the rapid termination of the acute inflammatory and infectious process to prevent irreversible parenchymal injury. In resource-poor settings, where laboratory support is often scarce, diagnostic algorithms utilizing basic clinical features are essential to distinguish this emergency from mimics ^[61]D5 (5).

Step 1: Emergency Stabilization and Airway Protection

Initial management focuses on the immediate stabilization of the patient's physiological state, particularly in those with a Glasgow Coma Scale ( GCS ) score ≤ 8 or rapidly declining consciousness.

• Airway Management: Secure the airway in patients with lethargy or loss of protective reflexes ^[79]C4 (4).
• Seizure Control: Convulsive status epilepticus is a frequent neurologic emergency in this setting, occurring in 12% of children with first-ever febrile status epilepticus ^[35]B2b (2b).
• Hemodynamic Support: Establish large-bore IV access and initiate fluid resuscitation to maintain cerebral perfusion pressure.

Step 2: Immediate Antimicrobial and Adjunctive Therapy

Time to antibiotics is the most critical determinant of survival. In a 15-year ICU cohort, the median time from hospital admission to antibiotics was 4.5 hours, though only 22.2% of patients received appropriate therapy within 1 hour ^[84]B3b (3b).

• Empiric Antibiotics: Initiate ceftriaxone immediately, especially in regions with high rates of penicillin-resistant or chloramphenicol-resistant bacteria ^[61]D5 (5). Resistance to ceftriaxone has been observed in 32.5% of pneumococcal isolates in some pediatric populations ^[85]B3b (3b).
• Adjunctive Steroids: Administer dexamethasone prior to or with the first dose of antibiotics. Increased utilization of dexamethasone (up to 80% of patients in recent cohorts) is associated with a significant reduction in severe disability at three months ^[84]B3b (3b).

Step 3: Management of Elevated Intracranial Pressure (ICP)

Elevated ICP is a hallmark of acute bacterial meningitis and is directly associated with increased mortality ^[82]A1a (1a).

• Monitoring: Invasive ICP monitoring, often via external ventricular drains (EVD), is used to both monitor and treat pressure through cerebrospinal fluid diversion ^[82]A1a (1a).
• Surgical Intervention: In cases of otogenic meningitis, surgery to sterilize the mastoid or tympanic cavity is indicated if initial medical treatment is not effective within 48 hours ^[81]A1c (1c). Most surgical interventions occur within 7 days of admission ^[81]A1c (1c).

Step 4: Neurorecovery and Arousal Promotion

For patients with persistent disorders of consciousness after the acute phase, pharmacologic strategies may be employed to enhance arousal.

• Amantadine: Amantadine 100-200 mg twice daily has been used off-label in the ICU to promote neurorecovery ^[80]A1a (1a).

Step 5: Transition to Definitive Care

Once the acute crisis is aborted, patients require structured monitoring for sequelae. Neurological sequelae affect more than 30% of survivors worldwide ^[39]A1a (1a). The pooled prevalence of sequelae at discharge is 24.8% in adults and 28.9% in children, necessitating a transition to long-term neurorehabilitation and follow-up ^[39]A1a (1a).

Controversies and Guideline Disagreement

Pearl: Administer ceftriaxone and dexamethasone within 1 hour of arrival; delays beyond this window are associated with increased neurologic sequelae, which affect nearly 25% of survivors at discharge ^{[39]A1a[84]B3b}.

Following the stabilization of neurologic emergencies, definitive management focuses on optimizing antimicrobial duration and administering adjunctive therapies to mitigate long-term neurologic sequelae. The therapeutic ladder for bacterial meningitis is heavily influenced by regional epidemiology , particularly the prevalence of HIV and the availability of intensive care resources.

Step 1: Definitive Antimicrobial Therapy

Antimicrobial selection is tailored to the pathogen identified via CSF analysis. While standard courses often extend to 14 days, evidence in specific populations suggests shorter durations may be feasible.

• Neonatal Meningitis: A randomized trial comparing 10 days versus 14 days of antibiotic therapy in neonates found no difference in treatment failure rates ^[94]A1b (1b). None of the 70 neonates in either group experienced a recurrence of meningitis within 28 days of enrollment ^[94]A1b.
• Infant Regimens: In infants under 60 days of age, the combination of benzylpenicillin plus gentamicin showed similar outcomes to ceftriaxone monotherapy, with mortality rates of 13.7% and 16.5% respectively ^[88]A1b (1b).

Step 2: Adjunctive Corticosteroid Therapy

The use of adjunctive dexamethasone is the most significant disease-modifying intervention, though its efficacy is highly dependent on the clinical setting and patient immune status.

• High-Income Settings: In adults with community-acquired meningitis, dexamethasone provides a significant survival benefit that persists for up to 20 years ^[1]A1b (1b). Long-term follow-up of the European Dexamethasone Study showed overall mortality was 22% in the dexamethasone group versus 33% in the placebo group (log-rank p = 0.029) ^[1]A1b.
• Pediatric Populations: A meta-analysis of 29 RCTs (N=3433) found that corticosteroids significantly reduced hearing loss (RR 0.62, 95% CI 0.47-0.81; NNT = 18 to prevent one case of hearing loss) ^[86]A1a (1a). Benefit was specifically observed with low-dose regimens (0.6 mg/kg per day) ^[86]A1a.
• HIV-Positive Adults and Resource-Poor Settings: In sub-Saharan Africa, where 90% of patients were HIV-positive, dexamethasone (16 mg twice daily for 4 days) failed to reduce mortality at 40 days (OR 1.14, 95% CI 0.79-1.64) ^[21]A1b (1b). Similarly, a meta-analysis confirmed no benefit in patients with a long duration of symptoms or those not receiving concomitant antibiotics ^[87]A1a (1a).

Step 3: Investigational and Alternative Adjuncts

Several agents have been trialed to reduce intracranial pressure or neuroinflammation with varying success.

• Acetaminophen: Rectal acetaminophen administered for the first 48 hours of antibiotic therapy did not affect mortality or neurologic outcomes in children ^[89]A1b (1b).

Step 4: Management of Complications and Monitoring

Controversies and Guideline Disagreement

Step 5: Risk Stratification for Discharge

Clinicians should utilize the Dutch Meningitis Cohort risk score to identify patients at high risk for unfavorable outcomes (GOS 1-4) ^[37]B2b (2b). The score incorporates six variables available within 1 hour of admission:

1. Age
2. Heart rate
3. Glasgow Coma Scale score
4. Cranial nerve palsies
5. CSF leukocyte count < 1,000 cells/mm³
6. Gram-positive cocci on Gram stain

Pearl: Adjunctive dexamethasone must be tailored to the environment; while it provides a 20-year survival benefit in high-resource settings, it increases mortality or provides no benefit in HIV-prevalent, resource-limited regions ^{[1]A1b[21]A1b[92]A1b}.

The therapeutic landscape for bacterial meningitis has transitioned from high-mortality conventional regimens to a standardized approach centered on rapid sterilization and the mitigation of host-mediated inflammation. While early management relied on combinations such as ampicillin and chloramphenicol , the emergence of third-generation cephalosporins and the validation of adjunctive corticosteroids have redefined the standard of care ^{[101]A1b[102]A1b}.

The Shift to Third-Generation Cephalosporins

In the 1980s and 1990s, clinical trials established third-generation cephalosporins as the backbone of therapy due to superior bactericidal activity and safety profiles compared to older agents.

• Ceftriaxone vs. Conventional Therapy: In pediatric cohorts, ceftriaxone demonstrated significantly greater mean bactericidal activity in the CSF compared to ampicillin plus chloramphenicol ^[101]A1b.
• Ceftriaxone vs. Cefuroxime: A landmark trial in children found ceftriaxone (100 mg/kg/day) superior to cefuroxime (240 mg/kg/day), resulting in more rapid CSF sterilization and a lower incidence of moderate-to-profound hearing loss (4% vs. 17%, P = 0.05) ^[97]A1b.
• Duration of Therapy: While 10-day courses were traditional, evidence from a multicountry equivalence study showed that in children stable by day 5 of ceftriaxone treatment, the antibiotic can be safely discontinued without increasing bacteriological failure or relapse ^[103]A1b.

The Dexamethasone Era

The introduction of adjunctive dexamethasone aimed to attenuate the subarachnoid inflammatory response triggered by bacterial lysis. The evidence for its use is highly dependent on the causative pathogen and the regional socioeconomic context.

• Adult Populations: The European Dexamethasone Study (2002) established that dexamethasone (10 mg every 6 hours for 4 days) administered 15-20 minutes before or with the first antibiotic dose reduced the risk of unfavorable outcomes (RR 0.59, 95% CI 0.37-0.94) and mortality (RR 0.48, 95% CI 0.24-0.96) ^[96]A1b. Long-term follow-up confirmed this survival benefit persists for up to 20 years ^[1]A1b.
• Pediatric Populations: Early administration of dexamethasone (0.15 mg/kg every 6 hours for 4 days) in children was shown to reduce meningeal inflammation and significantly lower the risk of neurologic or audiologic sequelae (RR 3.8 for placebo vs. dexamethasone, 95% CI 1.3-11.5) ^[98]A1b.
• Geographic Disparities: Trials in sub-Saharan Africa (Malawi) failed to show a benefit for dexamethasone in either adults or children, likely due to high rates of advanced HIV infection, malnutrition, and late clinical presentation ^{[21]A1b[100]A1b}. In these settings, dexamethasone did not reduce mortality or morbidity ^[21]A1b.

Evolution of Preventive Strategies

The development of conjugate vaccines has fundamentally altered the epidemiology and treatment necessity for specific pathogens. The introduction of the Meningococcal group A conjugate vaccine (PsA-TT) in the African Meningitis Belt achieved ≥93% seroconversion in infants ^[110]A1b. Similarly, the multicomponent recombinant meningococcal serogroup B vaccine (4CMenB) has demonstrated 100% immune response (hSBA titre ≥5) against test strains in infants after three doses ^[105]A1b. These advancements shift the focus toward a Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation to further refine long-term outcomes.

Abandoned and Alternative Approaches

• Chloramphenicol: Once a staple, chloramphenicol was found inferior to cephalosporins due to higher rates of bacteriological failure and the need for treatment extensions ^[102]A1b. However, in resource-limited settings, long-acting chloramphenicol remains a useful first-line presumptive treatment where intravenous access is limited ^[104]A1b.
• Cefuroxime: Abandoned as a primary meningitis treatment due to slower CSF sterilization and higher rates of hearing impairment compared to ceftriaxone ^[97]A1b.

Pearl: Adjunctive dexamethasone must be administered prior to or with the first dose of antibiotics to be effective; its benefit is most pronounced in pneumococcal meningitis in high-income settings, reducing mortality by approximately 50% (RR 0.48) ^[96]A1b.

Transitioning from empirical to definitive therapy requires integrating microbiological data with real-time hemodynamic and neuroimaging feedback. While historical management focused solely on pathogen eradication, modern programs emphasize the modulation of the host inflammatory response and the prevention of secondary neurologic injury through structured escalation and de-escalation protocols.

Step 1: Initial Severity and Disposition

Clinicians must first stratify patients based on neurologic and systemic stability. In critically ill patients, intracranial pressure (ICP) monitoring is essential; aggressive measures to maintain ICP <20 mmHg (including external ventriculostomy, osmotherapy, and temporary hyperventilation) have demonstrated effectiveness in reducing mortality ^[125]D5 (4). For patients with advanced HIV, mortality is significantly predicted by a change in sensorium and the presence of seizures ^[121]B3b (3b).

Step 2: Definitive Antimicrobial Sequencing

Once a pathogen is identified, therapy must be tailored to regional resistance patterns and specific microbiological findings.

• Community-Acquired: Initial bactericidal therapy should be rapid; dexamethasone is recommended as adjunctive therapy in developed countries to mitigate inflammatory damage ^[125]D5 (5).
• Anaerobic and Complex Infections: In cases of anaerobic meningitis (e.g., from oral flora), a combined regimen of meropenem and metronidazole is utilized, often requiring prolonged courses of 6 weeks ^[124]C4 (4).
• Pediatric Escalation: In ME-panel negative pediatric cases with abnormal CSF, off-label BCID2 testing can identify pathogens and resistance genes (e.g., VIM, vanA/B, CTX-M), leading to treatment escalation in 56.5% of cases ^[128]B3b (3b).

Step 3: Safety Monitoring and Pharmacovigilance

Monitoring must encompass both drug toxicity and physiologic response to therapy. Therapeutic drug monitoring (TDM) is recommended to individualize anti-infective protocols, particularly for complex brain abscesses or resistant organisms ^[124]C4 (4).

Step 4: Immunotherapy and De-escalation

De-escalation is guided by clinical stability and the resolution of inflammatory markers. While experimental therapies such as matrix metalloproteinase inhibitors or complement factor C5 inhibitors appear promising, they have not yet reached standard clinical practice ^[125]D5 (5). In neonatal populations, the surface polysaccharide Poly-β-(1-6)-N-Acetyl Glucosamine (PNAG) has been identified as a potential target for passive and active immunization against Escherichia coli K1 and Group B Streptococcus ^[127]D5 (5).

Controversies and Guideline Disagreement

Pearl: Maintain ICP <20 mmHg through aggressive intervention and utilize TDM to individualize therapy in complex or resistant infections to reduce the high mortality associated with neurologic deterioration ^{[124]C4[125]D5}.

Longitudinal management of survivors focuses on the mitigation of neurological sequelae, which affect more than 30% of patients worldwide ^[39]A1a. While acute management prioritizes sterilization of the cerebrospinal fluid (CSF), the transition to neurorehabilitation requires systematic screening for deficits that often manifest or intensify after hospital discharge ^[39]A1a, ^[130]B2b.

Neurological Sequelae and Monitoring

Detection of sequelae varies significantly by the timing of assessment. In adults, the pooled prevalence of neurological outcomes is 24.8% at discharge, rising to 41.5% within 3 months post-infection ^[39]A1a. Systematic follow-up is essential to identify evolving pathologies such as post-infectious adhesive arachnoiditis , which can lead to cord tethering and central cord damage years after the index infection ^[48]C4.

Common long-term impairments include:

• Hearing Loss: Occurs in approximately 15% of meningococcal survivors ^[130]B2b and is a primary sequela in both adult and pediatric populations ^[39]A1a.
• Neurocognitive Deficits: Approximately 10% of survivors report persistent concentration difficulties ^[130]B2b.
• Psychological Burden: Depressive symptoms affect more than 30% of patients, and nearly 40% report persistent sleep dissatisfaction ^[130]B2b.
• Focal Deficits: Includes cranial nerve palsies, hemiparesis, and ataxia ^[39]A1a.

Sensory Rehabilitation

Cochlear implantation (CI) is the standard for auditory rehabilitation in patients with severe to profound hearing loss secondary to bacterial meningitis ^[134]A1a. Early intervention is critical because post-meningitis ossification of the cochlea can complicate electrode insertion. Outcomes are influenced by the duration of deafness and the specific surgical technique, such as cochleostomy or circumodiolar drill-out ^[134]A1a.

Management of Secondary Neurological Syndromes

Clinicians must remain vigilant for immune-mediated or structural complications that arise during or after the acute phase.

• Guillain-Barre syndrome (GBS): Rare cases of GBS, characterized by progressive flaccid quadriparesis and albuminocytologic dissociation, have been reported following bacterial meningitis (e.g., E. coli). Management requires intravenous immunoglobulin (IVIG) and intensive rehabilitation ^[71]C4.
• Adhesive Arachnoiditis: Chronic inflammation can cause CSF sequestration and cord tethering. Patients may present with "man-in-the-barrel" syndrome (proximal arm weakness with preserved leg strength). Diagnosis often requires CT myelography to visualize contour irregularities of the conus medullaris ^[48]C4.

Supportive Care and Quality of Life

Supportive care aims to return patients to baseline functional status, though approximately 13% of previously active adults are unable to resume work at one year ^[130]B2b. Quality of life (QoL) metrics, including the SF-12 and EQ-5D-3L, frequently show significant physical and mental component deficits compared to age-matched populations ^[130]B2b, ^[131]B2b.

Pearl: Because the prevalence of neurological sequelae nearly doubles between hospital discharge (24.8%) and the 3-month follow-up (41.5%), a formal outpatient neuro-rehabilitative assessment is mandatory for all survivors ^[39]A1a.

Neurologic and systemic complications occur in approximately 39% to 50% of adults with bacterial meningitis and are the primary drivers of the 30% in-hospital mortality rate ^[24]C4, ^[52]B3b. While neurologic deterioration is the leading cause of death in younger patients, systemic complications account for 59% of fatal episodes in patients aged 60 years and older ^[24]C4.

Neurologic Complications

Cerebral injury arises from an uncontrolled host inflammatory response, often involving the complement system and neutrophil extracellular traps (NETs) that disrupt cerebrospinal fluid (CSF) transport ^[66]D5, ^[74]D5.

• Seizures and Status Epilepticus: Seizures occur in 17% of adult episodes, typically within the first 24 hours of admission ^[32]B2b. Convulsive status epilepticus (CSE) is a major emergency; in pediatric cohorts, CSE is associated with bacterial meningitis (RR 2.6) and carries a 15% in-hospital mortality rate ^[23]B2b.
• Cerebrovascular Events: Ischemic stroke occurs in approximately 16% of patients, primarily due to vasculopathy near the infection focus ^[59]A1a. While most infarcts occur within the first week, a delayed cerebral thrombosis can occur 7 to 19 days after initial recovery, particularly in pneumococcal cases ^[47]C4.
• Intracranial Pressure and Collections: Diffuse brain swelling and hydrocephalus are common. Infratentorial empyema is a rare but life-threatening complication often associated with sinusitis or mastoiditis; it frequently requires neurosurgical intervention as conservative antibiotic therapy is linked to relapse ^[60]C4.
• Hearing Loss: Sensorineural hearing loss is the most frequent long-term sequela, affecting approximately 24% to 34% of survivors ^[135]A1a, ^[40]A1a.

Systemic and Critical Care Complications

Severe meningitis often necessitates mechanical ventilation and intensive care unit (ICU) management due to both neurologic and systemic failure ^[52]B3b.

• Septic Shock and Organ Failure: Septic shock, acute kidney injury, and coagulation disorders are independent predictors of unfavorable 90-day outcomes ^[52]B3b.
• Autonomic and Respiratory Status: The FOUR score (Full Outline of Unresponsiveness) is used to monitor brainstem reflexes and respiration status, providing predictive value for mortality (AUC 0.68) ^[62]B2b.

Complication Management and Prevention

Long-term Sequelae

More than 30% of survivors experience persistent disabilities ^[39]A1a. Beyond hearing loss, these include cognitive dysfunction (21% in pneumococcal survivors), impaired executive function, and reduced short-term memory ^[46]A1b, ^[75]B3b. Unlike traumatic brain injury, the use of amantadine (100-200 mg twice daily) to promote arousal in stroke-related consciousness disorders has limited evidence in meningitis ^[80]A1a.

Pearl: Systemic complications, rather than primary neurologic failure, are the leading cause of death in elderly patients with bacterial meningitis, necessitating aggressive management of shock and organ dysfunction alongside antimicrobial therapy ^[24]C4.

Bacterial meningitis remains a critical emergency where outcomes are dictated by the interplay of pathogen virulence and the host inflammatory response. Despite the availability of effective antibiotics , mortality and morbidity rates remain high, particularly in adults with pneumococcal disease ^[10]D5[12]D5.

Survival and Mortality Trajectories

Global mortality has declined since 1990, yet the disease caused 259,000 deaths in 2023 ^[27]B2c. In the United States, the annual burden is approximately 4,100 cases and 500 deaths ^[26]B2c. Mortality rates vary significantly by setting and pathogen:

• General Adult Population: Case fatality rates in the United States are approximately 14.3% to 15.7% ^[26]B2c. In a Danish cohort, 30-day mortality was 13% and 1-year mortality reached 19% ^[45]B2b.
• Pneumococcal Meningitis: This etiology carries a higher risk, with in-hospital mortality of 30% in adults ^[24]C4.
• Critically Ill Patients: Among mechanically ventilated adults, 90-day mortality is 31.3% ^[52]B3b.
• Resource-Poor Settings: In sub-Saharan Africa, mortality is substantially higher; a trial in Malawi reported 40-day mortality of approximately 53% to 56% ^[21]A1b.

Predictors of Unfavorable Outcome

Early risk stratification is possible using clinical and laboratory markers. An unfavorable outcome (Glasgow Outcome Scale 1-4) occurs in approximately 34% of adult episodes ^[37]B2b.

Long-term Sequelae and Neuropsychological Impact

Survivors frequently face permanent disabilities. Approximately 21% of children in some cohorts develop neurological sequelae ^[23]B2b.

• Cognitive and Memory Deficits: Adults surviving pneumococcal meningitis have a 21% rate of cognitive dysfunction ^[46]A1b. Compared to viral meningitis, bacterial survivors show more frequent impairment in short-term memory, working memory, and executive functions ^[75]B3b.
• Hearing Loss: Dexamethasone may reduce hearing loss among survivors (24.1% vs 29.5%, p=0.04) ^[135]A1a.
• Epilepsy: Late unprovoked seizures are common, particularly after Streptococcus pneumoniae infection, and are associated with early acute-phase seizures and persistent neurological deficits ^[36]D5.

Impact of Adjunctive Therapy

The survival benefit of adjunctive dexamethasone is primarily realized in the acute phase. In European adults, the benefit remains evident for years; overall mortality was 22% in the dexamethasone group versus 33% in the placebo group over a median 13-year follow-up (log-rank p=0.029) ^[1]A1b. However, this benefit is not universal. In sub-Saharan Africa, dexamethasone did not reduce mortality or morbidity (OR 1.14, 95% CI 0.79-1.64) ^[21]A1b.

Pearl: The prognosis of bacterial meningitis is often fixed within the first hour of presentation; a CSF leukocyte count < 1,000 cells/mm³ or a low Glasgow Coma Scale score are high-intensity red flags for an unfavorable 90-day outcome ^{[24]C4[37]B2b}.

Prognostic outcomes and management strategies for bacterial meningitis shift significantly across the lifespan, as the burden of disease has increasingly moved toward older adults following the success of pediatric conjugate vaccines ^[26]B2c. While the overall incidence in the United States declined by 31% (95% CI, -33 to -29) between 1998 and 2007, the median age of patients rose from 30.3 to 41.9 years ^[26]B2c.

Pediatrics

Pediatric presentations often involve high morbidity, with 24% of children experiencing neurological sequelae ^[39]A1a. In school-age children (5-17 years), cerebral abscess or empyema occurs as frequently as meningitis (52% vs 48%) ^[44]B2b.

• Diagnostic Considerations: The updated PECARN rule identifies low-risk febrile infants (≤28 days) using negative urinalysis, serum procalcitonin ≤0.5 ng/mL, and absolute neutrophil count ≤4000/mm³. This rule demonstrated a sensitivity of 94.2% (95% CI, 85.6-97.8%) and a negative predictive value of 99.4% (95% CI, 98.1-99.8%) for invasive bacterial infections ^[141]B2b.
• Complications: Cerebral sinovenous thrombosis (CSVT) occurs in 31% of children with acute bacterial intracranial infections ^[30]B3b. Risk factors for CSVT include mastoiditis (aOR 12.2), cerebritis (aOR 4.6), and dehydration (aOR 3.9) ^[30]B3b.
• Pharmacokinetics: Elevated estimated glomerular filtration rate (eGFR ≥169.21 mL/min/1.73 m²) is associated with poor clinical outcomes in children receiving vancomycin , likely due to subtherapeutic trough concentrations ^[142]B3b. The initial vancomycin trough in children with elevated eGFR was 5.60 mg/L compared to 9.20 mg/L in those with normal eGFR ^[142]B3b.

Pregnancy and Neonatal Risk

Pregnancy is a primary risk factor for CNS invasion by Listeria monocytogenes , a Gram-positive pathogen that can cause meningoencephalitis, ventriculitis, and rhombencephalitis ^[25]C4. Universal screening of pregnant women for Group B Streptococcus (GBS) has altered the epidemiology , yet GBS remains the second most common cause of bacterial meningitis (18.1%) in the general population ^[26]B2c.

Elderly Patients

In patients aged 60 years and older, the clinical trajectory is dominated by systemic rather than neurological failure ^[24]C4.

• Mortality Drivers: Systemic complications are the cause of death in 59% of fatal episodes in the elderly, whereas neurological complications cause 65% of deaths in younger patients ^[24]C4.
• Prognostic Factors: Independent predictors for unfavorable outcomes in pneumococcal meningitis include a low Glasgow Coma Scale score, cranial nerve palsies, raised ESR, CSF leukocyte count <1000 cells/mm³, and high CSF protein ^[24]C4.

Immunocompromised Hosts

While Listeria typically targets the immunocompromised, elderly, or pregnant, lineage II serotypes can cause rapidly progressive ventriculitis and death even in healthy, young, immunocompetent hosts ^[25]C4. Clinicians must maintain high suspicion for Listeria in patients with exposure history (e.g., undercooked meats) who fail to improve on empiric ceftriaxone and vancomycin ^[25]C4.

Pearl: In pediatric patients, an eGFR ≥169.21 mL/min/1.73 m² is a critical threshold for vancomycin under-dosing and predicts poor clinical outcomes ^[142]B3b.

Prevention strategies for bacterial meningitis focus on reducing the global burden of disease through systematic vaccination and targeted screening of high-risk populations. While mortality and incidence have declined significantly since 1990, the disease caused 259,000 deaths and 2.54 million incident cases globally in 2023 ^[27]B2c. Children younger than 5 years remain disproportionately affected, accounting for more than one-third of these deaths ^[27]B2c.

Primary Prevention: Vaccination

Vaccination remains the most effective tool for eliminating preventable meningitis. The introduction of conjugate vaccines has led to a 55% decline in bacterial meningitis rates in the United States during the early 1990s ^[26]B2c.

• Haemophilus influenzae type b (Hib): Routine vaccination can almost completely eliminate Hib disease ^[22]A1a. In the year 2000, Hib caused approximately 8.13 million serious illnesses and 371,000 deaths in children aged 1-59 months ^[22]A1a. Near elimination has been documented in regions with long-standing vaccine programs ^[34]D5.
• Streptococcus pneumoniae: The 13-valent pneumococcal conjugate vaccine ( PCV13 ) covers serotypes responsible for 81.3% of confirmed pediatric cases in some high-burden regions ^[53]B3b. However, the emergence of non-vaccine serotypes (NVTs) and multidrug-resistant strains underscores the need for higher-valency vaccines, such as the 20-valent PCV20 , which has demonstrated robust immunogenicity in adults ^{[77]B3b[146]B2b}.
• Neisseria meningitidis: Conjugate vaccines have achieved near elimination of serogroup C in several high-income countries ^[34]D5. Prevention efforts now focus on the African meningitis belt using serogroup A conjugate vaccines ^[34]D5.

Screening and Risk Stratification

Screening programs target modifiable risk factors and vulnerable populations to interrupt transmission and reduce mortality.

• Maternal Screening: Universal screening of pregnant women for Group B streptococcus (GBS) has significantly altered the epidemiology of neonatal meningitis ^[26]B2c.
• Risk Factors: Top risk factors for meningitis-related mortality include low birthweight, short gestation, and household air pollution ^[27]B2c.
• Zoonotic Surveillance: Suspicion should be raised in patients with animal contact or consumption of animal products, particularly in immunocompromised individuals ^[28]D5.

Surveillance and Secondary Prevention

Continuous surveillance is required to monitor serotype replacement and antimicrobial resistance (AMR) trends. Global AMR in S. pneumoniae for benzylpenicillin is 27.4%, with resistance increasing in low-income and middle-income countries ^[41]A1a.

Pearl: Vaccination has shifted the burden of bacterial meningitis toward older adults, with the median age of patients in the United States increasing from 30.3 to 41.9 years as pediatric vaccine coverage expanded ^[26]B2c.